June 2026 Research Update

This month included one real-world report suggesting that Acthar Gel (repository corticotropin injection) was often followed by physician-perceived improvement in people with dermatomyositis/polymyositis. The pattern in this report was that improvement was described for most patients, and the changes doctors were aiming for were practical ones such as fewer symptoms and less limitation in daily function. Because the information came from a survey-based review of charts without a comparison group, it cannot show how much improvement was due to the medication versus other factors, but it adds to the picture of how this drug is being used and what outcomes are being looked for in routine care. [1]

In the dermatomyositis/polymyositis group (104 adults), physicians reported improved health status after Acthar Gel in 100 people (96%). Doctors also noted treatment goals in the dermatomyositis/polymyositis group that included improving overall symptoms, strength, and physical function and reducing corticosteroid use. This helps clarify what improvement looked like in this report: not just lab changes, but day-to-day symptoms and steroid burden as well. [1]

For patients and caregivers, this adds a real-world snapshot of how doctors describe Acthar Gel response in dermatomyositis/polymyositis, with a focus on symptoms and function rather than only test results. The evidence here is based on physician reports from charts and did not include a matched comparison group, so it is best viewed as descriptive rather than proof of effectiveness. It may matter now mainly as context about what outcomes are commonly tracked and discussed (pain, fatigue, physical function, and steroid use), and it may matter later if similar findings are confirmed in more controlled studies. [1]

This month strengthened an important point about myositis blood tests: results can vary depending on which commercial test is used and how the lab decides what counts as positive. Across two studies, agreement was high for several antibodies, but certain antibodies showed more disagreement and potential false positives, especially on some line blot or line immunoassay formats. In plain terms, these studies support the idea that a positive antibody result is not always equally reliable across all antibody types, and the details of the test can matter. [2] [3]

In a large Asia-Pacific comparison of ELISA versus line blot testing in inflammatory myopathy samples, many antibodies matched well between tests, but anti-PL-7 and anti-Mi-2 were notable exceptions. When discordant results were checked using a separate method, the line blot had a high rate of false positives for PL-7 and Mi-2, and ELISA was reported as more accurate. This matters because these antibody labels can be used to describe a subtype of myositis, and disagreement can create confusion about what type a person has. [2]

A second study looked specifically at a line immunoassay panel (EUROLINE) and tried an adjusted way of setting the positivity cutoff, called a positive control band index, to reduce the problem of people testing positive for multiple myositis antibodies at once. Using the revised cutoffs reduced (but did not eliminate) multiple-antibody positivity, and the adjusted approach slightly improved how well antibody patterns lined up with clinical diagnoses in the authors' analysis. The practical message is that even within the same test family, changing the cutoff rules may change which results are considered meaningful. [3]

For patients, this mainly affects understanding and interpretation of blood test results rather than pointing to a new treatment. These studies help clarify why two people with similar symptoms might get different antibody results at different labs, or why a person might be told they have more than one myositis antibody. What remains uncertain is how best to standardize testing across all labs and all antibody types, since these papers focused on specific commercial tests and specific antibodies. This is most relevant now as background for discussions about diagnosis and subtype labeling, and it may matter more later if testing standards become more consistent across regions and labs. [2] [3]

This month added several pieces about polymyositis in broader health contexts, rather than focusing on muscle symptoms alone. A hospital cohort study and several single-patient reports showed that polymyositis can show up together with lung disease, liver inflammation, or other autoimmune conditions, and care sometimes depends on recognizing the full combination. A separate genetics-based analysis explored whether having polymyositis might be linked to the risk of immune thrombocytopenia (a low-platelet autoimmune condition), but this kind of study is an early step and does not predict what will happen to an individual person. [4] [5] [6] [7]

In a single-center cohort of people with autoimmune pulmonary alveolar proteinosis (a rare lung condition where material builds up in air sacs), 10 out of 100 had another autoimmune disease, including 1 person with polymyositis and 1 with dermatomyositis. In most of these 10 people, the autoimmune disease came before the lung condition, and many had been on immunosuppressive treatment when the lung condition was diagnosed. This study does not say polymyositis causes this lung disease, but it documents that the overlap can occur and describes the timing pattern seen in that clinic. [4]

One genetics-based Mendelian randomization analysis reported a potential causal association between polymyositis and idiopathic thrombocytopenic purpura (ITP), with an odds ratio below 1 in the main analysis. This kind of result is about population-level genetic signals rather than symptoms or lab results in individual patients, and the paper noted limits such as the number of genetic instruments available. The immediate value is that it identifies a relationship that may be worth checking in future studies using larger genetic datasets or clinical cohorts. [7]

Two case reports illustrated how polymyositis can be part of complex, individualized situations, and a third, in the closely related condition dermatomyositis, addressed a diagnostic problem. One person with polymyositis-associated interstitial lung disease and severe malnutrition gained weight and muscle mass after intensive nutrition plus rehabilitation, including electrical muscle stimulation and exercise training, without reported metabolic complications. Another person had polymyositis-systemic sclerosis overlap with autoimmune hepatitis and a rare anti-Ku antibody pattern, with normalization of muscle and liver enzymes within 5 months on prednisolone plus mycophenolate mofetil. In the third report, a man whose tests confirmed dermatomyositis had a specialized nuclear medicine scan used to guide a repeat muscle biopsy after an initial biopsy was not diagnostic, leading to diagnostic tissue and reported clinical remission afterward. [5] [6] [8]

For patients, these studies mainly add awareness that polymyositis can overlap with other autoimmune problems or lung and liver complications, and that workups and care plans may need to consider more than muscles alone. Most of this section is based on a single-center cohort study and individual case reports, so it is best read as examples of what can happen rather than what usually happens. The genetics analysis is early research that may matter later if confirmed, because it points to a possible relationship between polymyositis and an autoimmune low-platelet condition. Taken together, this month helps clarify the range of situations researchers are paying attention to, while leaving open how common these overlaps are in the broader polymyositis community. [4] [7] [5] [6]